A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Brian Gastman, Steven Fling, George Ansstas, Pauline Funchain, Ann W. Silk, Philip Adam Friedlander, Brendan D. Curti, Yan Xing, Oanh Nguyen, Ann Christensen, Sara Ferrando-Martinez, Andreanne Lacroix, Byung Ha Lee, David M. Miller, Jeffrey A. Sosman, Jean Fan
Institutions: Cleveland Clinic Lerner College of Medicine, Fred Hutch Cancer Center, Washington University in St. Louis, Cleveland Clinic, Dana-Farber Cancer Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Providence Portland Medical Center, City Of Hope National Medical Center, NeoImmuneTech, Inc. (United States), Massachusetts General Hospital, Northwestern University, Northwestern Medicine
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4282053318